Cancer patients in India, already affected by shortages of critical chemotherapy drugs, are now set to face higher costs after the government approved a price hike.Facing significant shortages are Cisplatin and Carboplatin — the two platinum-based drugs that form the backbone of treatment for common cancers such as oral cancer, breast cancer, ovarian cancer, cervical cancer, esophageal cancer, and testicular cancer.Shortages Disrupt Cancer TreatmentThe shortage of these essential chemotherapy medicines is disrupting care across hospitals and cancer centers, with several doctors pointing out that a substantial proportion of chemotherapy protocols for solid tumors rely on one of these platinum-based agents.The drugs have been facing shortages as companies find it difficult to sustain production amid rising manufacturing costs linked to the ongoing conflict in the Middle East.The two drugs, often prescribed in combination and with no alternatives, are derived from platinum, a precious metal whose cost has surged due to the Middle East conflict and the closure of the Strait of Hormuz. Rising Production Costs Hit ManufacturersAlso read: India Revises Folic Acid Measurement Unit to Prevent Dosage Errors"The production cost has increased because the API, or active pharmaceutical ingredient, which is imported from abroad, has become more expensive. As a result, manufacturing costs have gone up, but the MRP has not increased," Dr Shyam Agarwal, Senior Consultant, Medical Oncology at Sir Ganga Ram Hospital, told HealthandMe.As companies have struggled to sustain production amid rising manufacturing costs, they approached the government seeking a revision of the price cap.Drugmakers reportedly sought price revisions for 82 medicines, citing substantial increases in production costs due to the US-Iran conflict linked to the Hormuz crisis and other factors.Government Approves Higher PricesIn response, the National Pharmaceutical Pricing Authority (NPPA), following permission from the Union government's Department of Pharmaceuticals (DoP), has increased maximum retail prices for four drugs, including the life-saving cancer medicines Cisplatin and Carboplatin, and two anti-tetanus injections.While the move is aimed at restoring supplies, it has also raised concerns about affordability for patients already battling a costly disease. The NPPA is the country's drug price regulator and functions under the DoP, Ministry of Chemicals and Fertilizers.NPPA Asked to Review Cost IncreasesRead More: India's Maternal Mortality Ratio Drops From 130 To 87 In Last 10 Years: Govt The ministry directed the pricing authority to determine how much prices could be increased. The formula suggested: "The Standing Committee recommended a 10 per cent increase per year from the last fixation with a ceiling of 50 per cent, which could also be a guide, but the primary principle should be cost increase," News18 reported.The DoP has further advised the NPPA to examine increases in raw material costs for these drugs while determining any price revisions. It has also asked the regulator to assess similar requests from the pharmaceutical industry, where price hikes have been sought due to higher raw material costs.